Clinical trial · Interventional
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The trial was stopped for futility in view of the results of the anticipated analysis
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of breast cancer. It is not yet known whether giving docetaxel together with a phytochemical is more effective than giving docetaxel alone in treating patients with breast cancer. PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with a phytochemical works compared with giving docetaxel alone as first- or second-line therapy in treating patients with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Curcumin | Dietary Supplement | — | UNRESOLVED |
| Taxotere | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Curcumine
- description
- With curcumin capsules
- interventionNames
- Dietary Supplement: Curcumin
- Drug: Taxotere
- type
- ACTIVE_COMPARATOR
- label
- Drug taxotere only
- description
- Without curcumin
- interventionNames
- Drug: Taxotere
Primary outcomes (1)
- measure
- Response rate as assessed by RECIST criteria
- timeFrame
- From the date of randomization until the end of the treatment, assessed up to 21 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed adenocarcinoma of the breast, meeting 1 of the following criteria:
* Locally advanced disease
* Documented metastatic disease without overexpression of Her2/neu
* Must have received prior anthracycline-containing regimen as neoadjuvant, adjuvant, or first-line chemotherapy for metastatic breast cancer
* Loco-regional recurrence not amenable to treatment by surgery or radiotherapy
* At least one measurable lesion according to RECIST criteria
* No bone lesion only disease
* Must be a candidate for taxane-based chemotherapy
* HER2-negative disease
* No symptomatic brain metastases
* Hormone receptor status not specified
PATIENT CHARACTERISTICS:
* Menopausal status not specified
* WHO performance status 0-2
* Life expectancy ≥ 3 months
* ANC ≥ 2,000/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 10 g/dL
* Serum creatinine \< 140 µmol/L OR creatinine clearance \> 60 mL/min
* Total bilirubin ≤ upper limit of normal (ULN)
* AST and ALT ≤ 1.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* Not pregnant or nursing
* Fertile patients must use effective contraception
* No history of significant neurologic (i.e., peripheral neuropathy ≥ grade 2) or psychiatric disorders, including psychotic disorders, dementia, or seizures that would prohibit the understanding, observance, and giving of informed consent
* No other prior or concomitant malignancies except adequately treated carcinoma in situ of the cervix uteri, basal cell or squamous cell carcinoma of the skin, or other cancer curatively treated with surgery and/or radiotherapy
* No concurrent severe and/or uncontrolled co-morbid medical condition
* No medically unstable patients
* No uncontrolled infection
* No autoimmune disease and/or chronic active inflammation
* No psychological, familial, social, or geographical reasons that would make clinical follow-up impossible
* No malabsorption syndrome or disease significantly affecting gastrointestinal function
* No dysphagia ≥ grade 2
* No history of hypersensitivity to taxanes or known excipients, including polysorbate 80
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior major resection of the stomach or proximal small bowel
* Prior hormonal therapy as adjuvant treatment and/or treatment of metastatic disease allowed provided that the patient has progressive disease at study entry
* Hormonal treatment must be discontinued prior to study entry
* No more than 1 prior chemotherapy regimen for metastatic disease
* More than 30 days since prior investigational drug
* More than 3 weeks since prior NSAIDs or COX\_2 inhibitors
* No other concurrent anticancer therapy
* No other concurrent dietary phytonutrientsReferences
Publications (0)
Data not yet available